A Randomized, Double-blind, Placebo-controlled Phase Ib Multiple-ascending Dose trial of APD 334 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2015
At a glance
- Drugs Etrasimod (Primary)
- Indications Autoimmune disorders; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Arena Pharmaceuticals
- 07 Jan 2015 Top-line results published in an Arena Pharmaceuticals media release.
- 03 Jun 2014 Status changed from planning to recruiting according to the Arena Pharmaceuticals media release.
- 06 Mar 2014 New trial record